Literature DB >> 23574541

Safety evaluation of desloratadine in allergic rhinitis.

Vanesa González-Núñez1, Antonio Valero, Joaquim Mullol.   

Abstract

INTRODUCTION: Desloratadine is a biologically active metabolite of second-generation antihistamine loratadine. It is also indicated for the treatment of allergic diseases, including allergic rhinitis. AREAS COVERED: A Medline search was conducted to identify preclinical and clinical studies of desloratadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of desloratadine. EXPERT OPINION: The review of these data indicates that the safety profile of desloratadine is similar to other second-generation antihistamines. Desloratadine is highly selective for histamine H₁-receptors, does not cross the blood-brain barrier (BBB), and has minimal adverse events (very low sedation rate), with a better safety and tolerability than first-generation antihistamines. Desloratadine is safe and well tolerated without having central nervous system (CNS) or cardiovascular effects and with low drug interaction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574541     DOI: 10.1517/14740338.2013.788148

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  4 in total

1.  A novel model of IgE-mediated passive pulmonary anaphylaxis in rats.

Authors:  Eva Wex; Eva Thaler; Sylvia Blum; David Lamb
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

2.  Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine.

Authors:  Tadaho Nakamura; Kotaro Hiraoka; Ryuichi Harada; Takuro Matsuzawa; Yoichi Ishikawa; Yoshihito Funaki; Takeo Yoshikawa; Manabu Tashiro; Kazuhiko Yanai; Nobuyuki Okamura
Journal:  Pharmacol Res Perspect       Date:  2019-07-12

3.  Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects.

Authors:  Jeltje Boer; Ellen Ederveen; Birgitta Grundmark
Journal:  Ups J Med Sci       Date:  2018-08-07       Impact factor: 2.384

4.  Desloratadine Exposure and Incidence of Seizure: A Nordic Post-authorization Safety Study Using a New-User Cohort Study Design, 2001-2015.

Authors:  Annette Kjær Ersbøll; Kaushik Sengupta; Eero Pukkala; Kristian Bolin; Eline Aas; Martha Emneus; Dena Rosen Ramey; Joanne E Brady; Daniel Mines; Kristian Aasbjerg; Christian Vestergaard; Gunnar Gislason; Alfred Peter Born; Thora Majlund Kjærulff
Journal:  Drug Saf       Date:  2021-10-05       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.